News

MHRA Manufacturing Licence for Avecia Biologics

Date: 13/05/2009

Avecia Biologics has announced it has received a Manufacturer’s Licence from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA). The Licence authorises commercial manufacturing at the company’s Tees Valley, UK site and comes three months after the company successfully underwent its first FDA Pre-Approval Inspection.

Avecia Biologics has been engaged in the development of innovative bioprocesses for over 30 years and has been making GMP material for clinical development for over 10 years. Based in the north-east of England, Avecia operates one of Europe’s largest cGMP contract manufacturing facilities and process development groups for microbial protein biologics, offering flexible capacity from 100L - 5000L for all stages of the product pipeline.

Steve Bagshaw, president of Avecia Biologics, said “we are immensely proud of achieving this significant milestone in our company’s development. It truly confirms us in the top tier of contract manufacturers for microbial biologics and we look forward to continuing to build on this success with our client partners”.


> DOWNLOAD PDF